Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
881-900 of 1,307 trials

Palmo-Plantars Warts: HPV Vaccine Study

We are testing a nonavalent HPV vaccine to see if it helps people with difficult-to-treat warts on their hands and feet. The study aims to improve wart clearance, pain, and overall quality of life.

HPV Vaccine>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteDermatologyInfectious Diseases

Lung Cancer Treatment: Nivolumab + Relatlimab with Chemotherapy

We are studying if a new combination treatment helps people with advanced non-small cell lung cancer live longer compared to standard treatment. This trial is for those whose cancer has spread or returned after previous treatment.

Advanced Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Heart Attack Recovery: Bempedoic Acid Study

We are investigating whether adding bempedoic acid to standard cholesterol medications helps heart attack patients reach their cholesterol goals. This study aims to improve treatment for those not meeting guidelines with current therapies.

Heart Attack1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Immunotherapy for Advanced Cancer: Standard vs. Reduced Dose

We are comparing standard immunotherapy treatment with a less frequent dosing schedule for patients with advanced cancer. The goal is to see if the reduced dose is just as effective and to evaluate its impact on quality of life and safety.

Advanced or Metastatic Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

Atrial Fibrillation: Dapagliflozin Treatment Study

We are investigating if dapagliflozin can help prevent the return of atrial fibrillation after cardioversion compared to usual care. This study aims to see how well it works in prolonging the time before atrial fibrillation recurs.

Atrial Fibrillation≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Breast Cancer Prevention: Denosumab for Women with BRCA1 Mutation

We are studying whether Denosumab can help prevent breast cancer in women carrying a BRCA1 mutation. This trial compares its effects to a placebo to see if it reduces cancer risk.

Breast Cancer Prevention in BRCA1 Mutation Carriers>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteHematologyOncology

Cystic Fibrosis: VX-121/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for children with cystic fibrosis to evaluate its safety and how well it works. This trial focuses on kids aged 1 to 11 years.

Cystic Fibrosis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Esophageal Cancer: Trastuzumab and Pertuzumab Study

We are studying if adding trastuzumab and pertuzumab to standard treatment helps improve survival for patients with HER2 positive esophageal adenocarcinoma. This trial involves patients whose cancer can be surgically removed.

HER2 Positive Esophageal Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Cardiogenic Shock: Levosimendan vs. Placebo

We are studying whether early use of levosimendan can improve health outcomes in patients with cardiogenic shock compared to a placebo. The goal is to see if it reduces the need for life support and improves survival rates.

Cardiogenic Shock>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Alzheimer's Agitation: Masupirdine Study

We are investigating whether masupirdine can help reduce agitation symptoms in people with Alzheimer's. The study will compare its effects to a placebo over 12 weeks.

Alzheimer's Disease3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Colorectal Cancer: Amivantamab with Chemotherapy

We are comparing a new treatment combining Amivantamab and chemotherapy to Cetuximab with chemotherapy for patients with certain types of colorectal cancer. This study aims to find out which option may help patients live longer without their cancer worsening.

Left-sided Colorectal CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Chronic Rhinosinusitis with Nasal Polyps: Tezepelumab Study

We are investigating how tezepelumab affects symptoms in adults with chronic rhinosinusitis and nasal polyps. The study looks at changes in nasal congestion, sense of smell, and overall quality of life.

Chronic Rhinosinusitis with Nasal Polyps3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Hypertrophic Cardiomyopathy: Sotagliflozin Study

We are investigating whether sotagliflozin can improve symptoms in people with hypertrophic cardiomyopathy. The study also looks at the safety of this treatment compared to a placebo.

Hypertrophic Cardiomyopathy6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Sickle Cell Disease: Gene Therapy with Lovocel

We are studying the long-term safety and effectiveness of a new gene therapy for people with sickle cell disease. This treatment uses modified stem cells to potentially improve health outcomes.

Sickle Cell DiseaseConfirmation phase (III)No PlaceboInvestigational MedicinesHematology

Advanced Breast Cancer: Capivasertib and Fulvestrant Study

We are researching the combination of capivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer who have not responded to standard treatments. The study aims to evaluate treatment effectiveness and safety in real-world clinical practice.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Semaglutide for Obesity and Resistant Hypertension

We are exploring whether semaglutide can help people with obesity and resistant hypertension better control their blood pressure compared to a placebo. This study aims to assess if this approach is feasible.

Resistant HypertensionObesity6-12 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Heart Failure and Kidney Disease: SENEKA Study

We are exploring a new treatment strategy for elderly patients with heart failure and chronic kidney disease to see if it helps manage potassium levels better. This study compares a potassium binder with standard medications to improve patient outcomes.

Chronic Heart Failure and Non-Dialysis Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

Sickle Cell Disease: CTX001 Treatment for Kids

We are studying a new gene-editing treatment for children with severe sickle cell disease. The trial aims to evaluate its safety and effectiveness in improving their health.

Sickle Cell Anaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

RAR-Immune: Nivolumab + Ipilimumab vs. Pazopanib for Advanced Sarcoma

We are studying whether a combination of nivolumab and ipilimumab works better than pazopanib alone for patients with advanced rare sarcomas. This trial will help us understand treatment effectiveness and patient quality of life.

Advanced Rare Sarcomas>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology